Background: Physical activity benefits people with type 1 diabetes (PwT1D); however, PwT1D appear less active than their nondiabetic peers. This study seeks to investigate the potential of diabetes technologies in mitigating perceived barriers to physical activity in type 1 diabetes (T1D).
Methods: A cross-sectional study with participants from the BETTER registry (age> 14 years) who completed BAPAD-1 (Barriers to Physical Activity in T1D) questionnaire. A significant barrier is defined by score > 5 to BAPAD-1 items. Four groups were defined according to the participants' treatment and blood glucose monitoring mode: Multiple daily injections (MDI) without continuous glucose monitoring (CGM), MDI with CGM, pump with CGM, and those using an automated insulin delivery system (AID).
Results: Among 1019 eligible participants, the main perceived barrier is the fear of hypoglycemia. The mean BAPAD-1 score is similar for all groups. A higher proportion of individuals using AID systems reported significant barriers for items fear of hypoglycemia and loss of control over their diabetes compared to the No-CGM-MDI (+20% both), CGM-MDI (+7% and +10%), and CGM+Pump (+9% and +7%).
Conclusion: Barriers to physical activity for PwT1D are not reduced by diabetes technologies. Some barriers are even perceived as more important for people using CGM, pump, and AID systems.
C. Guédet: None. S. Tagougui: None. V. Messier: None. V. Boudreau: None. A. Brazeau: Other Relationship; Dexcom, Inc. Research Support; Canadian Institutes of Health Research, Juvenile Diabetes Research Foundation (JDRF), Diabète québec, Fonds de recherche du Québec en Santé. R.P.R. Rabasa-Lhoret: Other Relationship; Abbott, AstraZeneca, Bayer Inc., Boehringer-Ingelheim, Dexcom, Inc. Research Support; Diabetes Canada. Other Relationship; Eli Lilly and Company. Research Support; Cystic Fibrosis Canada, Canadian Institutes of Health Research, FFRD - Fondation Francophone pour la Recherche du Diabète. Other Relationship; Janssen Pharmaceuticals, Inc. Research Support; Juvenile Diabetes Research Foundation (JDRF). Other Relationship; Novo Nordisk, GlaxoSmithKline plc. Consultant; HLS Therapeutics Inc., Insulet Corporation. Speaker's Bureau; CPD Networks. Other Relationship; Medtronic. Consultant; Pfizer Inc. Speaker's Bureau; Tandem Diabetes Care, Inc. Other Relationship; Sanofi. Speaker's Bureau; Vertex Pharmaceuticals Incorporated. Research Support; SFD - Société Francophone du Diabète.
